Every 424B that Illumina Inc (ILMN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ILMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ILMN filings page.
Illumina, Inc. is offering $300,000,000 aggregate principal amount of 4.950% Notes due 2029. The senior unsecured Notes pay interest semiannually on March 19 and September 19, beginning March 19, 2027, and mature on September 19, 2029. They will be issued in minimum denominations of $2,000 and will not be listed on any securities exchange.
Illumina expects net proceeds of about $297 million, to be used with cash on hand to repay its $500.0 million 4.650% notes due September 9, 2026. As of June 28, 2026, Illumina had $2.0 billion of total debt, including four other $500.0 million note issues, and no secured debt outstanding.
The Notes are senior unsecured obligations ranking equally with Illumina’s other unsecured senior debt and structurally subordinated to obligations of its subsidiaries, which had about $831 million of liabilities as of June 28, 2026. Illumina may redeem the Notes at its option (including a par call from August 19, 2029), and must offer to repurchase them at 101% plus accrued interest upon a Change of Control Triggering Event.
Illumina, Inc. plans a new offering of senior unsecured Notes under its automatic shelf registration, with specific maturity and coupon to be set at pricing. The Notes will be unsubordinated obligations, ranking equally with Illumina’s existing unsecured notes and effectively junior to any secured debt and to all liabilities of subsidiaries.
The company discloses existing indebtedness of $2.0 billion as of June 28, 2026 and subsidiary liabilities of $831 million. The Notes are callable at Illumina’s option, and upon a Change of Control Triggering Event holders may require repurchase at 101% of principal plus accrued interest. Illumina expects to use net proceeds for general corporate purposes, including repaying its 4.650% notes due September 9, 2026, of which $500.0 million was outstanding as of June 28, 2026. The Notes will be issued in minimum denominations of $2,000, in book-entry form through DTC, with no sinking fund and no planned exchange listing.
Illumina, Inc. is offering $500,000,000 aggregate principal amount of senior unsecured 4.750% notes due December 12, 2030. The notes pay interest semiannually on June 12 and December 12, beginning June 12, 2026, and are issued in $2,000 minimum denominations. They were priced at 99.962% with a 0.600% underwriting discount, resulting in gross proceeds of $496,810,000; estimated net proceeds are approximately $494,829,000.
Illumina intends to use the proceeds for general corporate purposes, which may include repaying its 5.800% notes due December 12, 2025 ($500 million outstanding as of September 28, 2025) and completing the proposed SomaLogic acquisition. The notes are unsecured and unsubordinated, ranking equally with Illumina’s other unsecured debt. They may be redeemed at Illumina’s option (make‑whole prior to the Par Call Date of November 12, 2030; at par thereafter), and include a change‑of‑control triggering event repurchase at 101% plus accrued interest.
The notes will not be listed; settlement is expected on or about November 25, 2025 (T+10). As context, Illumina reported $2.0 billion of debt and subsidiaries’ liabilities of approximately $818.0 million as of September 28, 2025.
Illumina, Inc. launched a preliminary prospectus supplement for a primary offering of senior unsecured notes. The Notes will pay interest semiannually and rank equally with Illumina’s existing unsecured debt, without subsidiary guarantees. They feature an issuer make-whole call prior to a defined par call date and are redeemable at 100% of principal on or after that date. If a change of control triggering event occurs, holders may put the Notes at 101% of principal plus accrued interest.
The company does not intend to list the Notes, and settlement is expected on a T+10 basis in book-entry form with minimum denominations of $2,000. Illumina states intended uses of proceeds include general corporate purposes, which may encompass repaying its 5.800% notes due December 12, 2025, of which $500.0 million was outstanding as of September 28, 2025, and funding the proposed acquisition of SomaLogic, including related fees and expenses.
As context, the Notes will be structurally subordinated to liabilities of subsidiaries and effectively subordinated to any future secured debt. Risk factors highlight limited covenants, potential rating changes, interest rate sensitivity that could affect trading prices, and the possibility that optional redemption could occur when rates are low.